# 6.0 510 (k) SUMMARY

SUBMITTED BY:

Mari A. Meyer   
Regulatory Affairs Specialist   
DiaSorin Inc.   
1951 Northwestern Avenue   
P.O. Box 285   
Stillwater, MN 55082-0285   
Phone (651) 351-5635   
Fax (651) 351-5669   
E-mail: mari.meyer@diasorin.com

NAME OF DEVICE:

Trade Name:

DiaSorin LIAISON® TOXO IgM

Common Names/Descriptions:

Immunoassay for the detection of IgM antibodies to Toxoplasma gondii

Classification Names:

Enzyme Linked Immunosorbent Assay, Toxoplasma

Product Code:

LGD

PREDICATE DEVICES:

DiaSorin Toxoplasma IgM ELISA Kit (K963289)

DEVICE DESCRIPTION:

# INTENDED USE:

The DiaSorin LIAISON® Toxo IgM assay uses chemiluminescent immunoassay (CLIA) technology on the LIAISON® Analyzer for the presumptive qualitative determination of IgM antibodies to Toxoplasma gondi in human serum.The LIAISO® Toxo IgM can be used as an aid in the presumptive diagnosis of acute or recent Toxoplasma gondii infection. It is recommended that the LIAlSON® Toxo IgM assay be performed in conjunction with a Toxoplasma gondii IgG assay.

This assay has not been cleared/approved by the FDA for blood/plasma screening.

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood, neonatal specimens, or infants.

# KIT DESCRIPTION:

The method for qualitative determination of IgM antibodies to Toxoplasma gondi (anti-Toxo IgM) is an antibody capture chemiluminescence immunoassay (CLIA). All assay steps (with the exception of magnetic particle resuspension) and incubations are performed by the LiAlSO® Analyzer. The principal components of the test are magnetic particles (solid phase) coated with igG to human IgM (mouse, monoclonal), Toxoplasma gondii antigen, and a conjugate of mouse monoclonal antibodies to Toxoplasma gondii linked to an isoluminol derivative isoluminol-antibody conjugate). During the first incubation, IgM antibodies present in diluted calibrators, samples or controls bind to the solid phase. During the second incubation, the mouse monoclonal antibody conjugate reacts with Toxoplasma gondii antigen previously added and the immune complex thus formed reacts with IgM already bound to the solid phase. After each incubation, the unbound material is removed with a wash cycle.Subsequently, the starter reagents are added and a flash chemiluminescence reaction is thus induced. The light signal, and therefore the amount of isoluminol-antibody conjugate, ismeasured by a photomultiplier as relative light units (RLU) and is indicative of the presence of anti-Toxo IgM in calibrators, samples or controls.

# PERFORMANCE DATA:

# COMPARATIVE CLINICAL TRIALS:

A total of 892 prospectively collected samples were tested - 613 collected from the U.S and 279 collected from Europe. The U.S. collection included 200 samples from pregnant women. The testing was performed at three sites  a hospital, a physician's laboratory, and at DiaSorin. All samples were tested with the LIAISON® Toxo IgG Assay and an enzyme immunoassay, ELISA. Equivocal results were not repeat tested per the manufacturers' recommendations; these results were not included in the calculations of overall agreement.

U.S. Prospective samples:

<table><tr><td rowspan=2 colspan=1>LIAISON® Toxo IgMResults</td><td rowspan=1 colspan=4>DiaSorin Toxo IgM ELISA Results</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive (&gt;= 10.0 AU)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Equivocal (8.0 - 9.9 AU)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt; 8.0 AU)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>408</td><td rowspan=1 colspan=1>410</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>409</td><td rowspan=1 colspan=1>413</td></tr></table>

<table><tr><td></td><td>Percent Agreement</td><td>Exact 95% confidence interval</td></tr><tr><td>Positive</td><td>33.3% (1/3)</td><td>0.8 - 90.6%</td></tr><tr><td>Negative</td><td>99.8% (408/409)</td><td>98.7 - 99.9%</td></tr><tr><td>Overall</td><td>99.3 % (409/412)</td><td>97.9 - 99.9%</td></tr></table>

European Prospective sample:   

<table><tr><td rowspan=2 colspan=1>LIAISON® Toxo IgMResults</td><td rowspan=1 colspan=4>DiaSorin Toxo IgM ELISA Results</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive (&gt;= 10 AU)</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>Equivocal (8.0- 9.9 AU)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Negative (&lt; 8.0 AU)</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>231</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>226</td><td rowspan=1 colspan=1>279</td></tr></table>

<table><tr><td></td><td>Percent Agreement</td><td>Exact 95% confidence interval</td></tr><tr><td>Positive</td><td>91.1% (41/45)</td><td>78.0 - 97.5%</td></tr><tr><td>Negative</td><td>98.7% (223/226)</td><td>96.2 - 99.7%</td></tr><tr><td>Overall</td><td>94.9% (265/279)</td><td>91.7 - 97.3%</td></tr></table>

Prospective samples: Pregnant Women   

<table><tr><td rowspan=2 colspan=1>LIAISON® TOxo IgMResults</td><td rowspan=1 colspan=3>ELISA Results</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>197</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>195</td><td rowspan=1 colspan=1>200</td></tr></table>

<table><tr><td></td><td>Percent Agreement</td><td></td><td>Exact 95% confidence interval</td></tr><tr><td>Positive:</td><td>33.3%</td><td>(1/3)</td><td>0.8 - 90.6%</td></tr><tr><td>Negative:</td><td>99.5%</td><td>(194/195)</td><td>97.2 - 99.9%</td></tr><tr><td>Overall:</td><td>98.5%</td><td>(195/198)</td><td>95.6 - 99.7%</td></tr></table>

# CDC PANEL STUDY:

The CDC (Centers for Disease Control and Prevention) Toxoplasma 1998 Human Serum Panel was tested by LIAISON® Toxo IgM assay. The panel is comprised of 100 frozen blinded specimens: 32 Toxoplasma IgM positive, 3 dilutions f three true Toxoplasma gM positive, and 6 Toxoplasma IgM negative samples.O the IgM negative samples 30 were Toxoplasma IgG negative and 35 IgG positive.The data obtained were suitt to the CDC for analysis. The LIAISON® Toxo IgM Assay correctly detected the 32 out of the $3 2 \mathsf { l g } \mathsf { M }$ positives, 1 the three Mpositiv iluts, and  e Megativs. oThe esulte pre mes tconveurhe inormation n the perforanc thi assay wit amaskecharacterizseru p This does not imply endorsement of the assay by the CDC.

# REPRODUCIBILITY:

An assay reproducibility study was conducted at two external US laboratories and at DiaSorin.A coded panel comprised of 9 frozen repository serum samples was prepared by DiaSorin and provided to each site for testing by the LIAlSoN Toxo IgM assay. The panel contained 3 sets of serum samples.The sets were prepared to represent low to mid positive analyte levels.All panel members were divided into alquots and stored frozen prior to testing.The same coded panel was tested at ll three sits, inre replicates per run for ten runs. The results are summarized below.

<table><tr><td>ID#</td><td>mean N (AU/mL)</td><td>within run S.D.</td><td>within run %CV</td><td>run S.D.</td><td>between between run %CV</td><td>site S.D.</td><td>n between between site %CV</td><td>overall sd.</td><td>overall</td></tr><tr><td>TMS1</td><td>90 33.1</td><td>3.08</td><td>9.18</td><td>9.12</td><td>12.54</td><td>6.04</td><td>18.26</td><td>7.57</td><td>%CV 22.89</td></tr><tr><td>TMS2</td><td>90 19.7</td><td>1.30</td><td>6.88</td><td>5.06</td><td>9.36</td><td>3.94</td><td>19.99</td><td>3.92</td><td>19.91</td></tr><tr><td>TMS3</td><td>90 847</td><td>47.1</td><td>5.71</td><td>187</td><td>8.52</td><td>91.9</td><td>10.87</td><td>120.3</td><td>14.21</td></tr><tr><td>TM1</td><td>90 24.4</td><td>1.70</td><td>6.65</td><td>7.38</td><td>10.33</td><td>6.23</td><td>25.48</td><td>6.10</td><td>24.96</td></tr><tr><td>TM2</td><td>90 34.0</td><td>2.08</td><td>5.74</td><td>12.26</td><td>9.77</td><td>11.49</td><td>33.78</td><td>10.71</td><td>31.48</td></tr><tr><td>TM3</td><td>90 26.7</td><td>1.95</td><td>7.17</td><td>7.55</td><td>8.20</td><td>6.03</td><td>25.57</td><td>6.04</td><td>22.63</td></tr><tr><td>TM4</td><td>90 25.9</td><td>1.65</td><td>6.14</td><td>8.35</td><td>8.67</td><td>7.17</td><td>27.65</td><td>6.91</td><td>26.67</td></tr><tr><td>TM5</td><td>90 14.0</td><td>0.97</td><td>6.83</td><td>3.57</td><td>8.73</td><td>2.44</td><td>17.46</td><td>2.64</td><td>18.84</td></tr><tr><td>TM6</td><td>90 18.8</td><td>0.88</td><td>4.52</td><td>6.00</td><td>8.62</td><td>5.16</td><td>27.41</td><td>4.95</td><td>26.31</td></tr></table>

\*TMS3 dose was below the reading range of the assay. Precision calculations are based on signal (RLU) for this sample.

# CROSS-REACTIONS:

Cross-reactivity studies for the LIAisON® Toxo IgM assay were designed to evaluate potential interference from IgM immunoglobulins directed against closely-related members of the herpes virus family (HSV-1, HSV-2, VZV, CMV),other organisms that may cause symptoms similar to Toxoplasmosis V, ubella vius, hepati  s,hepattisvius)ancondns that may result from al immune system activity (rheumatoid factor (RF), anti-nuclear antibodies (ANA)). Samples for these studies were selected using commercially available devices.

<table><tr><td rowspan=1 colspan=1>Organism/condition</td><td rowspan=1 colspan=1>Number of ExpectedNegative Samples</td><td rowspan=1 colspan=1>LIAISONPositive Result</td></tr><tr><td rowspan=1 colspan=1>HAV Total</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>(0/9)</td></tr><tr><td rowspan=1 colspan=1>HBcTotal</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>(0/21)</td></tr><tr><td rowspan=1 colspan=1>VZVIgM</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>(0/8)</td></tr><tr><td rowspan=1 colspan=1>Rubella IgM</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>(0/7)</td></tr><tr><td rowspan=1 colspan=1>CMV IgM</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>(0/13)</td></tr><tr><td rowspan=1 colspan=1>VCA IgM</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>(0/14)</td></tr><tr><td rowspan=1 colspan=1>HSV1-2 IgM</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(0/10)</td></tr><tr><td rowspan=1 colspan=1>ANA</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(0/10)</td></tr><tr><td rowspan=1 colspan=1>RF</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(0/10)</td></tr><tr><td rowspan=1 colspan=1>HAMA</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(0/10)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>112</td><td rowspan=1 colspan=1>(0/112)</td></tr></table>

No positive result was found for the samples when tested by LIAlSON® Toxo IgM.

WARNING: Assay interference due to circulating antibodies against HIV and Hepatitis C virus has not been evaluated. The user is responsible for establishing cross-reactivity performance with these infectious agents.

# INTERFERING SUBSTANCES:

Controlled studies of potentially interfering substances showed that the assay performance was not affected by hemolysis (at 1000 mg/dL hemoglobin), lipemia (at 3000 mg/dL triglycerides), icterus (at 20 mg/dL bilirubin).

# 6.0 510 (k) SUMMARY

SUBMITTED BY:

Mari A. Meyer   
Regulatory Affairs Specialist   
DiaSorin Inc.   
1951 Northwestern Avenue   
P.O. Box 285   
Stillwater, MN 55082-0285   
Phone (651) 351-5635   
Fax (651) 351-5669   
E-mail: mari.meyer@diasorin.com

NAME OF DEVICE:

Trade Name:

DiaSorin LIAISON® TOXO IgG

Common Names/Descriptions:

Immunoassay for the detection of IgG antibodies to Toxoplasma gondii

Classification Names:

Enzyme Linked Immunosorbent Assay, Toxoplasma

Product Code:

LGD

PREDICATE DEVICES:

Diamedix Is-Toxoplasma IgG ELISA Kit (K981498)

DEVICE DESCRIPTION:

# INTENDED USE:

The LIAISON® Toxo IgG assay uses chemiluminescent immunoassay (CLIA) technology on the LIAISON® Analyzer (Catolog number 15970) for the the qualitative determination of specific IgG antibodies to Toxoplasma gondi in human serum.The results of this assay can be used as an aid in the assessment of the patient's serological status to infection with Toxoplasma gondii and in the determination of immune status of individuals including pregnant women.

This assay has not been cleared/approved by the F.D.A for blood/plasma donor screening.

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood, neonatal specimens, or infants.

KIT DESCRIPTION: The method for qualitative determination of IgG antibodies to Toxoplasma gondii (anti-Toxo IgG) is an indirect chemiluminescence immunoassay (CLIA). All assay steps (with the exption f magnetic particle resuspension) and incubations are performed by the LIAlSo® Analyzer. The principal components of the test are magnetic particles (solid phase) coated with Toxoplasma gondi and a conjugate of mouse monoclonal antibodies to human IgG linked to an isoluminol derivative isoluminol-antibody conjugate). During the first incubation, Toxoplasma gondii antibodies present in diluted calibrators, samples or controls bind to the solid phase. During the second incubation, the monoclonal antibody conjugate reacts with anti-Toxo IgG that is already bound to the solid phase.After e incubation, unbound material is removed with a wash cycle.Subsequently, the starter reagents a added and a flash chemiluminescence reaction is thus induced. The light signal and therefore, the amount of isoluminol-antibody conjugate, is measured by a photomultiplier as relative light units (RLU) and is indicative of the presence of anti-Toxo IgG in calibrators, samples or controls.

# COMPARATIVE CLINICAL TRIALS:

A total of 887 prospectively collected samples were tested - 613 collected from the U.S and 274 collected from Europe. The U.S. collection included 200 samples from pregnant women. In adition, 200 archived samples from acute, chronic, and normal patients were tested The testing was performed at four sites.All samples were tested with the LIAISON® Toxo IgG Assay and an enzyme immunoassay ELISA or Sabin Feldman Dye test.

Equivocal results were not repeat tested per the manufacturers' recommendations; these results were not included in the calculations of overall agreement.

U.S. Prospective samples:

<table><tr><td rowspan=2 colspan=1>LIAISON® Toxo IgGResults</td><td rowspan=1 colspan=3>ELISA Results</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>87</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>304</td><td rowspan=1 colspan=1>313</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>319</td><td rowspan=1 colspan=1>413</td></tr></table>

<table><tr><td colspan="2"></td><td>Percent Agreement</td><td>Exact 95% confidence interval</td></tr><tr><td>Positive</td><td>91.8%</td><td>(78/85)</td><td>83.8 - 96.6%</td></tr><tr><td>Negative</td><td>95.3%</td><td>(304/319)</td><td>92.4 - 97.3%</td></tr><tr><td>Overall</td><td>93.5%</td><td>(386/413)</td><td>90.6 - 95.6%</td></tr></table>

European Prospective samples:   

<table><tr><td rowspan=2 colspan=1>LIAISON® Toxo IgGResults</td><td rowspan=1 colspan=3>ELISA Results</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>149</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>119</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>274</td></tr></table>

<table><tr><td></td><td>Percent Agreement</td><td>Exact 95% confidence interval</td></tr><tr><td>Positive</td><td>98.6% (139/141)</td><td>94.9 - 99.8%</td></tr><tr><td>Negative</td><td>91.3% (116/127)</td><td>85.0 - 95.6%</td></tr><tr><td>Overall</td><td>94.5% (255/268)</td><td>91.9 - 97.4%</td></tr></table>

Prospective samples: Pregnant Women   

<table><tr><td rowspan=2 colspan=1>LIAISON® Toxo IgGResults</td><td rowspan=1 colspan=3>ELISA Results</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>145</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>200</td></tr></table>

<table><tr><td colspan="2"></td><td>Percent Agreement</td><td>Exact 95% confidence interval</td></tr><tr><td>Positive:</td><td>96.0%</td><td>(48/50)</td><td>86.3 - 99.5%</td></tr><tr><td>Negative:</td><td>97.3%</td><td>(143/147)</td><td>91.2 - 99.2%</td></tr><tr><td>Overall:</td><td>96.5%</td><td>(190/197)</td><td>92.8 - 98.6%</td></tr></table>

Retrospective Samples:   

<table><tr><td rowspan=2 colspan=1>LIAISON® ToxoIgG Results</td><td rowspan=1 colspan=3>Sabin Feldman Dye test Results</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>149</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>200</td></tr></table>

<table><tr><td></td><td colspan="2">Percent Agreement</td><td>Exact 95% confidence interval</td></tr><tr><td>Positive</td><td>99.3%</td><td>(149/150)</td><td>96.3 - 99.9%</td></tr><tr><td>Negative</td><td>100.0%</td><td>(0/0)</td><td>92.0 - 100.0</td></tr><tr><td>Overall</td><td>99.5%</td><td>(49/50)</td><td>97.2 - 99.9%</td></tr></table>

# CDC PANEL STUDY:

The CDC (Centers for Disease Control and Prevention) Toxoplasma 1998 Human Serum Panel was tested by LIAlSON® Toxo IgG assay. The panel is comprised of 100 frozen blinded specimens, 70 Toxoplasma positive samples and 30 toxoplasma negative samples. The data obtained were submitted to the CDC for analysis. The LIAISON® Toxo IgG Assay correctly detected the 70 positive and the 30 negative specimens.Note: These results are presented as a means to convey further information on the performance of this assay with a masked, characterized serum panel.This does not imply endorsement of the assay by the CDC.

# REPRODUCIBILITY:

An assay reproducibility study was conducted at two external US laboratories and at DiaSorin.A coded panel comprised of 9 frozen repository samples was prepared by DiaSorin and provided to each site for testing by the LIAlSON® Toxo IgG assay.The panel contained samples prepared to represent low to mid positive analyte levels.Al panel members were divided into aliquots and stored frozen prior to testing. The same coded panel was tested at all three sites, in three replicates per run for ten uns.The rsults are summarized below.

<table><tr><td>ID#</td><td>mean (IU/mL) N</td><td>within run S.D.</td><td>within run %CV</td><td>run S.D.</td><td>between between run %CV</td><td>site S.D.</td><td>between between site %CV</td><td>overall sd.</td><td>iloverall %CV</td></tr><tr><td>TGS1</td><td>90 16.4</td><td>0.38</td><td>2.31</td><td>3.23</td><td>7.02</td><td>0.59</td><td>3.62</td><td>1.35</td><td>8.26</td></tr><tr><td>TGS2</td><td>33.4 89</td><td>0.18</td><td>2.88</td><td>1.46</td><td>5.07</td><td>0.81</td><td>2.42</td><td>0.46</td><td>5.94</td></tr><tr><td>TGS3</td><td>90 12.9</td><td>0.16</td><td>1.57</td><td>1.33</td><td>4.95</td><td>0.82</td><td>6.38</td><td>0.36</td><td>7.22</td></tr><tr><td>TG1</td><td>90 7.6</td><td>0.96</td><td>2.38</td><td>6.37</td><td>4.96</td><td>0.28</td><td>3.68</td><td>1.99</td><td>6.05</td></tr><tr><td>TG2</td><td>90 8.1</td><td>0.18</td><td>2.18</td><td>1.54</td><td>4.25</td><td>0.30</td><td>3.69</td><td>0.45</td><td>5.58</td></tr><tr><td>TG3</td><td>90 11.1</td><td>0.19</td><td>1.92</td><td>1.72</td><td>5.27</td><td>0.29</td><td>2.61</td><td>0.47</td><td>6.22</td></tr><tr><td>TG4</td><td>90 7.1</td><td>0.20</td><td>2.22</td><td>2.50</td><td>4.08</td><td>0.20</td><td>2.89</td><td>0.93</td><td>5.07</td></tr><tr><td>TG5</td><td>90 9.1</td><td>0.21</td><td>2.07</td><td>2.13</td><td>3.50</td><td>0.32</td><td>3.45</td><td>0.69</td><td>5.17</td></tr><tr><td>TG6</td><td>90 10.4</td><td>0.21</td><td>2.02</td><td>1.99</td><td>4.78</td><td>0.35</td><td>3.34</td><td>0.60</td><td>5.79</td></tr></table>

# CROSS-REACTIONS:

Cross-reactivity studies for the LIAISON® Toxo IgG assay were designed to evaluate potential interference from igG immunoglobulins directed against closely-related members of the herpes virus family (HSV-1, HSV-2, VZV, CMV), other organisms that may cause symptoms similar to Toxoplasmosis V,ubela vius,hepatiis  vs,heaisBvius)ancos hat may resul fromayl immune system activity [rheumatoid factor (RF), anti-nuclear antibodies (ANA)]. Samples for these studies were selected using commercially available devices.

<table><tr><td rowspan=1 colspan=1>Organism/condition</td><td rowspan=1 colspan=1>Number of ExpectedNegative Samples</td><td rowspan=1 colspan=1>LIAISONPositive Result</td></tr><tr><td rowspan=1 colspan=1>HAV Total</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>(0/12)</td></tr><tr><td rowspan=1 colspan=1>HBc Total</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>(0/17)</td></tr><tr><td rowspan=1 colspan=1>VZV IgG</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>(0/8)</td></tr><tr><td rowspan=1 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>(0/5)</td></tr><tr><td rowspan=1 colspan=1>CMV IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>(0/10)</td></tr><tr><td rowspan=1 colspan=1>VCA IgG</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>(0/12)</td></tr><tr><td rowspan=1 colspan=1>HSV1-2 IgG</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>(0/2)</td></tr><tr><td rowspan=1 colspan=1>ANA</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>(0/7)</td></tr><tr><td rowspan=1 colspan=1>RF</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>(0/8)</td></tr><tr><td rowspan=1 colspan=1>HAMA</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>(0/7)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>(0/88)</td></tr></table>

No positive result was found for the samples when tested by LIAlSON® Toxoplasma IgG.

# WARNING: Assay interference due to circulating antibodies against HIV and Hepatitis C virus has not been evaluated. The user is responsible for establishing cross-reactivity performance with these infectious agents.

# INTERFERING SUBSTANCES:

Controlled studies of potentially interfering substances showed that the assay performance was not affected by hemolysis (at 1000 mg/dL hemoglobin), lipemia (at 3000 mg/dL triglycerides) or icterus (at 20 mg/dL bilirubin).

# FEB 8 2006

Ms. Mari Meyer   
Regulatory Affairs Specialist DiaSorin Inc.   
1951 Northwestern Avenue P.O. Box 285   
Stillwater, MN 55082-0285

Re: k052499 Trade/Device Name: LIAISON® Toxo IgG LIAISON® Toxo IgM Regulation Number: 21 CFR 866.3780 Regulation Name: Toxoplasma gondii Serological Reagents Regulatory Class: Class II Product Code: LGD Dated: January 5, 2006 Received: January 6, 2006

Dear Ms. Meyer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or classIII (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA mav publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice reauirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legaily marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

$$
\sin a \pi , a \pi \gamma \pi \gamma \pi
$$

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K0 2499

Device Name:

LIAISON® Toxo IgG

Indications For Use:

The LIAISON® Toxo IgG assay uses chemiluminescent immunoassay (CLIA) technology on the LIAISON® Analyzer for the the qualitative determination of specific IgG antibodies to Toxoplasma gondii in human serum. The results of this assay can be used as an aid in the assessment of the patient's serological status to infection with Toxoplasma gondii and in the determination of immune status of individuals including pregnant women.

This assay has not been cleared/approved by the F.D.A for blood/plasma donor screening.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) k052499

# Indications for Use

510(k) Number (if known): 1: K052499

Device Name:

LIAISON® Toxo IgM

Indications For Use:

The LIAISON® Toxo IgM assay uses   
chemiluminescent immunoassay (CLIA) technology on the LIAlSON® Analyzer for the presumptive qualitative   
determination of IgM antibodies to Toxoplasma gondii in human serum. The LIAISON® Toxo IgM can be used as an aid in the presumptive diagnosis of acute or recent   
Toxoplasma gondii infection. It is recommended that ihe LIAISON® Toxo IgM assay be performed in conjunction with a Toxoplasma gondii IgG assay.

This assay has not been cleared/approved by the F.D.A for blood/plasma donor screening.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Office of In Vitro Diagnostic Device Evaluation and Safety

Page 1 of 1

![](images/c27ab4a2c23057f5600f1fa48c2fc31cb5fde9cf3ffaeadce1d209aa20d0d50f.jpg)  
Page 4

![](images/dfb716885345c801596d45ba327b1b52ed51ddaea0afe4b70c149f796699fa55.jpg)  
Volume I1